Lalage M. Wakefield: BIBLIOGRAPHY Date prepared: 6-23-14

PEER-REVIEWED JOURNALS

1. Buckland, R.M., Radda, G.K., and **Wakefield, L.M.**: Reconstitution of the chromaffin granule ATPase. FEBS Lett. 103: 323-327, 1979.

2. Buckland, R.M., Radda, G.K., and **Wakefield, L.M.**: The role of phospholipids in the modulation of enzyme activities of the chromaffin granule. Biochim. Biophys. Acta 643: 363-375, 1981

3. **Wakefield, L.M.**, Cass, A.E.G., and Radda, G.K.: Isolation of membrane protein by chromatofocusing: Cytochrome b-561 of the adrenal chromaffin granule. J. Biochem. Biophys. Methods 9: 331-341, 1984.

4. Frolik, C.A., **Wakefield, L.M.,** Smith, D.M., and Sporn, M.B.: Characterization of a membrane receptor for transforming growth factor-ß in normal rat kidney fibroblasts. J. Biol. Chem. 259: 10995-11000, 1984.

5. Roberts, A.B., Anzano, M.A., **Wakefield, L. M.**, Roche, N.S., Stern, D. F., and Sporn, M. B.: Type ß transforming growth factor: A bifunctional regulator of cell growth. Proc. Natl. Acad. Sci. USA 82: 119-123, 1985.

6. Anzano, M.A., Roberts, A.B., De Larco, J.E., **Wakefield, L.M.**, Assoian, R.K., Roche, N.S., Smith, J. M., Lazarus, J. E., and Sporn, M. B.: Increased secretion of type ß transforming growth factor accompanies viral transformation of cells. Mol. Cell. Biol. 5: 242-247, 1985.

7. Rook, A.H., Kehrl, J. H., **Wakefield, L.M.**, Roberts, A. B., Burlington, D. B., Lane, H. C., Sporn, M.B., and Fauci, A.S.: Effects of transforming growth factor ß in the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 136: 3916-3920, 1986.

8. Kehrl, J. H., **Wakefield, L.M.**, Roberts, A.B., Jakowlew, S., Alvarez-Mon, M., Derynck, R., Sporn, M.B., and Fauci, A.S.: The production of TGF-ß by human T-lymphocytes and its potential role in the regulation of T-cell growth. J. Exp. Med. 163: 1037-1050, 1986.

9. Masui, T., **Wakefield, L.M.,** Lechner, J. F., Laveck, M.A., Sporn, M.B., and Harris, C.C.: Type ß transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells. Proc. Natl. Acad. Sci. USA 83: 2438-2442, 1986.

10. Fanger, B.O., **Wakefield, L.M**., and Sporn, M.B.: Structure and properties of the cellular receptor for transforming growth factor type ß. Biochemistry 25: 3083-3091, 1986.

11. Roberts, A.B., Sporn, M.B., Assoian, R.K., Smith, J.M., Roche, N.S., **Wakefield, L.M.**, Heine, U.I., Liotta, L.A., Falanga, V., Kehrl, J.H., and Fauci, A.S.: Transforming growth factor-ß: Rapid induction of fibrosis and angiogenesis *in vivo* and stimulation of collagen formation *in vitro*. Proc. Natl. Acad. Sci. USA 83: 4167-4171, 1986.

12. **Wakefield, L.M.**, Cass, A.E.G., and Radda, G.K.: Functional coupling between enzymes of the chromaffin granule membrane. J. Biol. Chem. 261: 9739-9745, 1986.

13. **Wakefield, L.M.**, Cass, A.E.G., and Radda, G.K.: Electron transfer across the chromaffin granule membrane: Use of EPR to demonstrate reduction of intravesicular ascorbate radical by the extravesicular mitochondrial NADH:ascorbate radical oxidoreductase. J. Biol. Chem. 261: 9746-9752, 1986.

14. Kehrl, J.H., Roberts, A.B., **Wakefield, L.M**., Jakowlew, S., Sporn, M.B., and Fauci, A.S.: Transforming growth factor-ß is an important immunomodulatory protein for human B lymphocytes. J. Immunol. 137: 3855-3860, 1986.

15. Knabbe, C., Lippman, M.E., **Wakefield, L.M**., Flanders, K. C., Kasid, A., Derynck, R. and Dickson, R.B.: Evidence that transforming growth factor-ß is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417-428, 1987.

16. O'Connor-McCourt, M.D. and **Wakefield, L.M**.: Latent transforming growth factor-ß in serum: a specific complex with alpha-2-macroglobulin. J. Biol. Chem. 262: 14090-14099, 1987.

17. **Wakefield, L.M.**, Smith, D.M., Masui, T., Harris, C.C. and Sporn, M.B.: Distribution and modulation of the cellular receptor for transforming growth factor-ß. J. Cell Biol. 105: 965-975, 1987.

18. Wahl, S., Hunt, K.A., **Wakefield, L.M**., Wahl, L.M., Roberts, A.B. and Sporn, M.B.: Transforming growth factor-ß induces monocyte chemotaxis and growth factor production. Proc. Natl. Acad. Sci. USA 84: 5788-5792, 1987.

19. **Wakefield, L.M.**, Smith, D.M., Flanders, K.C., and Sporn, M.B.: Latent transforming growth factor-ß from human platelets: a high molecular weight complex containing precursor sequences. J. Biol. Chem. 263: 7646-7654, 1988.

20. **Wakefield, L.M.**, Smith, D.M., Broz, S., Jackson, M., Levinson, A.D., and Sporn, M.B.: Recombinant transforming growth factor-ß1 is synthesized as a two-component latent complex that shares some structural features with the native platelet latent TGF-ß complex. Growth Factors, 1: 203-219, 1989.

21. Brown, P.D., **Wakefield, L.M**., Levinson, A.D., and Sporn, M.B.: Physicochemical activation of recombinant latent transforming growth factors-ßs 1, 2 and 3. Growth Factors, 3: 35-43, 1990.

22. **Wakefield, L.M**., Winokur, T.S., Hollands, R.S.,, Christopherson, D., Levinson, A.D., and Sporn, M.B.: Recombinant latent transforming growth factor-ß1 has a longer plasma half-life in rats than active transforming growth factor-ß1, and a different tissue distribution. J. Clin. Invest. 86: 1976-1984, 1990.

23. Colletta, A.A., **Wakefield, L.M**., Howell, F.V., van Roozendaal, K.E.P., Danielpour, D., Ebbs, S.R., Sporn, M.B., and Baum, M.: Anti-oestrogens induce the secretion of active transforming growth factor-ß from human fetal fibroblasts. Br. J. Cancer, 62: 405-409, 1990.

24. Colletta, A.A., **Wakefield, L.M.**, Howell, F.V., Danielpour, D., Baum, M. and Sporn, M.B.: The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor-ß. J. Clin. Invest. 87: 277-283, 1991.

25. Bonewald, L.F., **Wakefield, L**., Oreffo, R.O.C., Escobedo, A., Twardzik, D.R., and Mundy, G.R.: Latent forms of transforming growth factor-ß (TGF-ß) derived from bone cultures: identification of a naturally occurring 100-kDa complex with similarity to recombinant latent TGF-ß. Mol. Endocrinol. 5: 741-751, 1991.

26. Brandes, M.E., **Wakefield, L.M.**, and Wahl, S.M.: Modulation of monocyte type I transforming growth factor-ß receptors by inflammatory stimuli. J. Biol. Chem. 266: 19697-19703, 1991.

27. **Wakefield, L.M.**, Kondaiah, P., Hollands, R.S., Winokur, T.S., and Sporn, M.B.: Addition of a C-terminal extension sequence to transforming growth factor-ß1 interferes with biosynthetic processing and abolishes biological activity. Growth Factors, 5: 243-253, 1991.

28. Kim, S-J., Park, K., Koeller, D., Kim K.Y., **Wakefield, L.M**., Sporn, M.B., and Roberts, A.B.: Post-transcriptional regulation of the human transforming growth factor-ß1 gene. J. Biol. Chem., 267: 13702-13707, 1992.

29. Butta, A., MacLennan, K., Flanders, K.C., Sacks, N.P.M., Smith, I., McKinna, A., Dowsett, M., **Wakefield, L.M**., Sporn, M.B., Baum, M., and Colletta, A.A.: Induction of transforming growth factor-ß1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res., 52: 4261-4264, 1992.

30. Ballock, R.T., Heydemann, A., **Wakefield, L.M.**, Flanders, K.C., Roberts, A.B., and Sporn, M.B.: TGF-ß1 prevents hypertrophy of epiphyseal chondrocytes: regulation of gene expression for cartilage matrix proteins and metalloproteases. Devel. Biol. 158: 414-429, 1993.

31. Ballock, R.T., Heydemann, A., **Wakefield, L.M.**, Flanders, K.C., Roberts, A.B., and Sporn, M.B.: Inhibition of the chondrocyte phenotype by retinoic acid involves upregulation of metalloprotease genes independent of TGF-ß. J. Cell Physiol. 159: 340-346, 1994.

32. Fiorelli, G., Ballock, R.T., **Wakefield, L.M.**, Sporn, M.B., Gori, F., Masi, L., Frediani, U., Tanini, A., Bernabei, P.A., and Brandi, M.L.: A role for autocrine TGF-ß1 in regulating the differentiation of an osteoclast precursor cell line. J. Cell. Physiol. 160:482-490, 1994.

33. **Wakefield, L.M.**, Letterio, J.J., Chen, T., Danielpour, D., Allison, R.S.H., Pai, L.H., Denicoff, A.M., Noone, M. H., Cowan, K. H., O'Shaughnessy, J.A., and Sporn, M.B.: Transforming growth factor-ß1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin. Cancer Res. 1:129-136, 1995.

34. Sanderson, N., Factor, V., Nagy, P., Kopp, J., Kondaiah, P., **Wakefield, L.**, Roberts, A., Sporn, M.B., and Thorgeirsson, S.S.: Hepatic expression of mature TGF-ß1 in transgenic mice results in multiple tissue lesions. Proc. Natl. Acad. Sci. USA, 92:2572-2576, 1995.

35. Grainger, D.J., **Wakefield, L.**, Bethell, H.W., Farndale, R.W., and Metcalfe, J.C.: Release and activation of platelet latent TGF-ß in blood clots during dissolution with plasmin. Nature Medicine 1:932-937, 1995.

36. Bottinger, E.P., Factor, V.M., Tsang, M. L-S., Weatherbee, J.A., Kopp, J.B., Qian, S-W., **Wakefield, L.M.,** Roberts, A.B., Thorgeirsson, S.S., and Sporn, M.B. The recombinant proregion of transforming growth factor-ß1 (LAP) inhibits active transforming growth factor-ß1 in transgenic mice. Proc. Natl. Acad. Sci. USA 93: 5877-5882, 1996.

37. Wojtowicz-Praga, A., Verma, U.M., **Wakefield, L.,** Esteban, J.M., Hartmann, D., and Mazumder, A.: Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor-ß antibody and interleukin-2. J. Immunotherapy 19:169-175, 1996.

38. Benson, J.R., **Wakefield, L.M**., Baum, M. and Colletta, A.A. Synthesis and secretion of TGF-ß isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen. Br. J. Cancer 74: 352-538, 1996.

39. Romeo, D., Allison, R.S.H., and **Wakefield, L.M.:** Recharacterization of the start sites for the major human transforming growth factor-ß1 mRNA. Gene, 189: 289-295, 1997.

40. Böttinger, E.P., Jakubczak, J.L., Roberts, I.S.D., Mumy, M., Hemmati, P., Bagnall, K., Merlino, G., **Wakefield, L.M.:** Expression of a dominant-negative mutant TGF-ß type II receptor in transgenic mice reveals essential roles for TGF-ß in regulation of growth and differentiation in the exocrine pancreas. EMBO J., 16:2621-2633, 1997.

41. Böttinger, E.P., Jakubczak, J.L., Haines, D.C., Bagnall, K. and **Wakefield, L.M.:** Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor-ß receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res. 57: 5564-5570, 1997.

42. Tang, B., Böttinger, E.P., Jakowlew, S.B., Bagnall, K.M., Mariano, J., Anver, M.R., Letterio, J.J., and **Wakefield, L.M.:** Transforming growth factor-ß1 is a new form of tumor suppressor with true haploid insufficiency. Nature Medicine 4: 802-807, 1998. PMID: 9662371

43. Yang, Y., Mumy, M., Romeo, D., **Wakefield, L.M**.: Identification of the start sites for the 1.9- and 1.4-kb rat transforming growth factor-ß1 transcripts and their effect on translational efficiency. Gene, 219: 81-89, 1998.

44. Allison, R.S.H., Mumy, M.L., **Wakefield, L.M.:** Translational control elements in the major human transforming growth factor-ß1 mRNA. Growth Factors, 16:89-100, 1998.

45. Zujewski, J., Pai, L., **Wakefield, L.**, Guisti, R., Dorr, F.A., Flanders, C., Caruso, R., Kaiser, M., Goodman, L., Merino, M., Gossard, M., Noone, M.A., Denicoff, A., Venzon, D., Cowan, K.H., O'Shaughnessy, J.A.: Tamoxifen and Fenretinide in Women with Metastatic Breast Cancer. Breast Cancer Research and Treatment, 57:277-283, 1999.

46. Tang, B., deCastro, K., Barnes, H.E., Parks, T., Stewart, L., Bottinger, E., Danielpour, D., and **Wakefield, L.M**.: Loss of Responsiveness to TGF-ß induces malignant transformation of non-tumorigenic rat prostate epithelial cells. Cancer Res., 59:4834-4842, 1999.

47. Kang Y., Mariano, J.M., Andgisen, J., Moody, T.W., Diwan, B.A., **Wakefield, L.M.**, and Jakowlew, S.B.: Enhanced Tumorigenesis and Reduced Trasnforming Growth Factor-β Type II Receptor in Lung Tumors from Mice with Reduced Gene Dosage of Transforming Growth Factor-β1. Mol. Carcinogenesis, 29:112-126, 2000.

48. Kang, Y., Prentice, M.A., Mariano, J.M., Davarya, S., Linnoila, R.I., Moody, T.W., **Wakefield, L.M**., and Jakowlew, S.B.: Transforming growth factor-β and its Receptors in Human Lung Cancer and Mouse Lung Carcinogenesis. Exp. Lung. Res., 26:685-707, 2000.

49. Zujewski, J., Vaughn-Cooke, A., Flanders, K.C., Eckhaus, M.A., Lubet, R.A., and **Wakefield, L.M**.: Transforming growth factors-β are not good biomarkers of chemopreventive efficacy in a preclinical breast cancer model system. Breast Can. Res., 3:66-75, 2001.

50. McKenna, I.M., Ramakrishna, G., Diwan, B.A., Kang, Y., Shiao, Y-H., **Wakefield, L.M.,** Powell, D.A., Anderson, L.M., and Jakowlew, S.B.: Heterozygous inactivation of TGF-β1 increases the susceptibility to chemically induced mouse lung tumorigenesis independently of mutational activation of K-ras. Toxicol. Lett., 123:151-158, 2001.

51. Morrisey, K., Evans, R.A., **Wakefield, L.M.**, and Phillips, A.O.: Translational Regulation of Renal Proximal Tubular Epithelial Cell Transforming Growth Factor-β1 Generation by Insulin. Am. J. Pathol., 159:1905-1915, 2001.

52. Yang, Y., Tang, B., Robinson, G., Hennighausen, L., Brodie, S.G., Deng, C-X., **Wakefield, L.M.:** Smad3 in the mammary epithelium has a non-redundant role in the induction of apopotsis, but not in the regulation of proliferation or differentiation by TGF-β. Cell Growth & Differentiation, 13:123-130, 2002

53. Yang, Y., Dukhanina, O., Tang, B., Mamura, M., Letterio, J.J., MacGregor, J., Patel, S.C., Khozin, S., Liu, Z., Green, J., Anver, M., Merlino, G., **Wakefield, L.M.:** Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side-effects. J. Clin. Invest. 109:1607-1615, 2002. PMID: 12070308

    - See related Commentary: TGF-β antagonists: Why suppress a tumor suppressor? J. Clin. Invest. 109:1533-1536, 2002

54. Fernandez, T., Amoroso, S., Sharpe, S., Jones, G.M., Bliskovski, V., Kovalchuk, A., **Wakefield, L.M.,** Kim, S-J., Potter, M., Letterio, J.J.: Disruption of TGF-β signaling by a novel ligand-dependent mechanism. J. Exp. Med. 195:1247-1255, 2002

55. Ewan, K.B., Shyamala, G., Ravani, S., Tang, Y., Akhurst, R., **Wakefield, L.,** Barcellos-Hoff, M.H.: Latent TGF-β activation in mammary gland: Regulation by ovarian hormones affects ductal and alveolar proliferation. Am. J. Path, 160:2081-2093, 2002

56. Fraser, D., **Wakefield, L.,** Philips, A.: Independent regulation of TGF-β1 transcription and translation by glucose and PDGF. Am. J. Path., 161:1039-1049, 2002

57. **Wakefield, L.M**., Thordarson, G., Nieto, A.I., Shyamala, G., Galvez, J.J., Anver, M.R., Cardiff, R.D.: Spontaneous pituitary abnormalities and mammary hyperplasias in FVB/NCr mice: implications for mouse modeling. Comparative Medicine, 53:352-360, 2003

58. Nieto, A.I., Shyamala, G., Galvez, J.J., **Wakefield, L.M**., Cardiff, R.D.: Persistent mammary hyperplasia in FVB/N mice. Comparative Medicine, 53:361-366, 2003

59. Tang, B., Vu, M., Booker, T., Santner, S.J., Miller, F.R., Anver, M.R., **Wakefield, L.M**.: TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J. Clin. Invest., 112:1116-1124, 2003 PMID: 14523048

    - See related Highlights article: Switching Roles. Nat. Rev. Cancer 3:805, 2003

60. Tian, F., Byfield, S., Parks, W.T., Yoo, S., Felici, A., Tang, B., Piek, E., **Wakefield, L.M.,** and Roberts, A.B.: Reduction in Smad 2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res., 63:8284-8292, 2003

61. Kaviratne, M., Hesse, M., Leusink, M., Cheever, A.W., Davies, S.J., McKerrow, J.H., **Wakefield, L.M.,** Letterio, J.J., Wynn, T.A. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-β independent. J. Immunol., 173:4020-4029, 2004

62. Nam, J-S., Suchar, A.M., Kang, M-J., Stuelten, C.H., Tang, B., Michalowska, A.M., Fisher, L.W., Fedarko, N.S., Jain, A., Pinkas, J., Lonning, S., and **Wakefield, L.M.** Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of TGF-beta in a mouse model of breast cancer. Cancer Res., 66: 6327-6335, 2006. PMID: 16778210

63. Nam, J-S., Kang, M-J., Suchar, A.M., Shimamura, T., Kohn, E.A., Michalowska, A.M., Jordan, V.C., Hirohashi, S., and **Wakefield, L.M.** Chemokine (C-C motif) ligand 2 (CCL2) mediates the pro-metastatic effect of dysadherin in human breast cancer cells. Cancer Res., 66: 7176-7184, 2006

64. Seth P, Wang ZG, Pister A, Zafar MB, Kim S, Guise T, **Wakefield L.** Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy. Hum Gene Ther.,17):1152-60, 2006.

65. Wildi, S., Kleeff, J., Mayerle, J., Zimmermann, A.,, Böttinger, E.P., **Wakefield, L.M.**, Büchler, M.W., Friess, H., and Korc, M. Suppression of TGF-beta signaling aborts caerulein-induced pancreatitis and eliminates restricted stimulation at high caerulein concentrations. Gut, 56:685-92, 2007

66. Varticovski L, Hollingshead MG, Robles AI, Wu X, Cherry J, Munroe DJ, Lukes L, Anver MR, Carter JP, Borgel SD, Stotler H, Bonomi CA, Nunez NP, Hursting SD, Qiao W, Deng CX, Green JE, Hunter KW, Merlino G, Steeg PS, **Wakefield LM**, Barrett JC. Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models. Clin Cancer Res. 13:2168-77, 2007. PMID: 17404101

67. Tang, B., Yoo, N., Vu, M., Mamura, M., Nam, J-S., Ooshima, A., Du, Z., Despresz, P-Y., Anver, M.R., Michalowska, A.M., Shih, J., Parks, W.T., and **Wakefield, L.M.** Transforming growth factor-β can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cells and committed progeny in a breast xenograft model. Cancer Res. 67:8643-8652, 2007. PMID: 17875704
    - *Highlighted article*

68. Stuelten, C.H., Kamaraju, A.K., **Wakefield, L.M.,** and Roberts, A.B. Lentiviral reporter constructs for fluorescence tracking of the temporospatial pattern of Smad3 signaling. Biotechniques 43:289-290, 2007. PMID:17907571

69. Nam, J-S., Terabe, M., Mamura, M., Kang, M-J., Chae,H., Stuelten, C., Kohn, E., Tang, B., Sabzevari,H., Anver, M.R., Lawrence, A., Danielpour,D., Lonning, S., Berzofsky, J., **Wakefield, L.M**., An anti-TGF-β antibody suppresses metastasis via cooperative effects on multiple cellular compartments. Cancer Res. 68:3835-3843, 2008. PMID: 18483268

70. Nam, J.S., Terabe, M., Kang, M-J., Chae, H., Voong, N., Yang, Y., Laurence, A., Michalowska, A., Mamura, M., Lonning, S., Berzofsky,J.A., and **Wakefield,L.M**., TGF-β subverts the immune system into directly promoting tumor growth through IL-17. Cancer Res. 68:3915-3923, 2008
    - *Highlighted article: side-bar on cover of issue*

- *Selected as one of the top NCI-CCR Science Advances of FY2008*

71. Stuelten, C.H., Katz, R., Busch, J.I., Roberts, A.B., **Wakefield, L.M.,** Barbul, A., and Niederhuber, J.E., Acute wounds accelerate tumorigenesis by a T-cell dependent mechanism. Cancer Res. 68:7278-7282, 2008. PMID: 18794114

72. di Bari, M.G., Lutsiak, M.E.C., Takai, S., Mostbock, S., Farsaci, B., Tolouei Semnani R., **Wakefield, L.,** Schlom, J., and Sabzevari, H. TGF-β modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression. Cancer Immunol. Immunother. 58:1811-1820, 2009. PMID: 19319531

73. Bian, Y., Terse, A., Du, J., Hall, B., Molinolo, A., Zhang, P., Chen, W., Flanders, K.C., Gutkind, J.S., **Wakefield, L.M.,** and Kulkarni, A.B. Progressive Tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res. 69:5918-5926, 2009. PMID: 19584284.

74. Kim, R-J., Kim, S-R., Roh, K-J., Park S-B., Park J-R., Kang, K-S., Kong, G., Tang, B., Yang, Y.A., Kohn, E.A., **Wakefield, L.M.,** and Nam, J-S. Ras activation contributes to the maintenance and expansion of Sca-1+ cells in a mouse model of breast cancer. Cancer Lett. 287:172-181, 2010. PMID: 19586713

75. Kadota, M., Sato, M., Dunca, B., Ooshima, A., Yang, H.H., Diza-Meyer, N., Gere, S., Kageyama, S-I., Fukuoka, J., Nagata, T., Tsukada, K., Dunn, B.K., **Wakefield, L.M.,** and Lee, M.P. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of *PIK3CA*. Cancer Research, 69:7357-7376, 2009. PMID: 19706770

76. Figueroa, J.D., Flanders, K.C., Garcia-Closas, M., Anderson, W., Yang, X.R., Matsuno, R., Duggan, M., Pfeiffer, R.M., Oshima, A., Cornelison, R., Gierach, G.L., Brinton, L.A., Lissowska, J., Peplonska, B., **Wakefield, L.M.,** and Sherman, M.E. TGF-beta pathway marker expression and breast cancer: heterogeneous relationships with age at diagnosis, tumor characteristics and risk factors in the Polish population-based case control study. Breast Cancer Res. Treat., 121:727-735, 2010. PMID: 19937272

77. Stuelten, C.H., Busch, J.I., Oshima, A., Karpova, T.S., **Wakefield, L.M.**, Roberts, A.B., and Niederhuber, J.E. Transient tumor-fibroblast interactions durably increase tumor cell malignancy by a TGF-β-mediated mechanism. PLoS One, 5:e9832, 2010. PMID: 20352126

78. Kadota, M., Sato, M., Yang, H.H., Gomez, B., Clifford, R.J., Dunn, B.K., **Wakefield, L.M.,** and Lee, M.P. Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One, 5:e9201, 2010. PMID 20169162

79. Mendoza, A., Hong, S.H., Osborne, T., Khan, A., Campbell, K., Briggs, J., Eleswarapu,A., Buquo, L., Ren, L., Hewitt, S.M., Dakir, E-H., Garfield, S., Walker, R., Merlino, G., Green, J.E., Hunter, K., **Wakefield, L.M,** Hong, S-H., and Khanna, C.

Modeling metastasis biology and therapy in real time in the mouse lung. J. Clin. Invest., 120:2979-2988, 2010. PMID: 20644255

80. Kohn,E.A., Du, Z., Van Schyndle, C.M.H., Tang, B., Ju, W., Bottinger, E.P. and **Wakefield, L.M.** A novel approach for the generation of genetically modified mammary epitihelial cell cultures yields new insights into TGF-beta signaling in the mammary gland. Breast Cancer Res. 12(5):R83, 2010. PMID: 20942910

81. Kohn,E.A., Yang, Y.A., Du, Z., Nagano, Y., Van Schyndle, C.M.H., Hermann, M.A., Heldman, M. Chen, J.Q., Stuelten, C.H., Flanders, K.C., and **Wakefield, L.M.** Biological responses to TGF-β in the mammary epithelium show a complex dependency on Smad3 gene dosage with important implications for tumor progression. Mol. Cancer Res. 10:1389-1399, 2012. PMID: 2287587

82. Matsubara,T., Tanaka,N., Sato,M., Kang, D.W., Krausz,K.W., Flanders,K.C., Ikeda,K., Luecke,H., **Wakefield,L.M.,** and Gonzalez,F.J. TGF-β-SMAD3 signaling mediates hepatic bile acid and phospholipid metabolism following lithocholic acid-induced liver injury. J. Lipid Res. 53:2698-707, 2012. PMID: 23034213

83. Stuelten,C.H., Cervoni,F.N., Busch, J.I., Sutton,E., Webster,J.D., Kavalukas,S.L., **Wakefield,L.M.,** Barbul,A. and Niederhuber,J.E. SDF-1α mediates wound-promoted tumor growth in a syngeneic orthotopic mouse model of breast cancer. PLOS One 8:e60919, 2013. PMID: 23593347

84. Hu,Y., Bai,L., Geiger,T., Goldberger,N., Walker,R.C., Green,J.E., **Wakefield,L.M.** and Hunter,K.W. Genetic background may contribute to PAM50 gene expression breast cancer subtype assignments. PLOS One 8:e72287, 2013. PMID: 24015230

85. Luger,D., Yang, Y., Raviv,A., Weinberg,D., Banerjee,S., Lee,M-J., Trepel,J., Yang,L. and **Wakefield,L.M.** Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effects. PLOS One 8:e76115, 2013. PMID: 24146823

86. Chen, X., Yang,Y., Zhou,Q., Weiss, J.M., Howard,O.M.Z., McPherson,J.M., **Wakefield, L.M.,** Oppenheim, J.J. Effective chemoimmunotherapy with anti-TGF-beta antibody and cyclophosphamide in a mouse model of breast cancer. PLOS One 9:e85398, 2014. PMID: 24416401

87. Li,X.L., Hara,T., Choi,Y., Subramamian,M., Francis,P., Bilke,S., Walker,R.L., Pineda,M., Zhu, Y., Yang, Y., Luo,J., **Wakefield, L.M.,** Brabletz,T., Park,B.H., Sharma,S., Chowdhury,D., Meltzer,P.S. and Lal,A. A p21-ZEB1 complex inhibits epithelial-to-mesenchymal transition through the microRNA 183-96-182 cluster. Mol. Cell Biol. 34:533-50, 2014. PMID: 24277930

88. Subramamian,M., Francis,P., Bilke,S., Li,X.L., Hara,T., Walker,R.L., Zhu,Y., Pineda,M., Lee,C., Varanasi,L., Yang,Y., Martinez,L.A., Luo,J., **Wakefield,L.M**., Meltzer,P.S. and Lal,A. A mutantp53/let-7i axis regulated network drives cell growth, invasion and metastasis. Oncogene, in press, 2014. PMID: 24662829

89. Sato,M., Kadota, M., Tang, B., Shan, M., Weng, J., Welsh,M.A., Flanders, K.C., Michalowski, A.M., Yang, H.H., Clifford, R.J., Lee, M.. and **Wakefield, L.M.** An integrated genomic approach identifies persistent tumor suppressive effects of TGF-beta in human breast cancer. Breast Cancer Res. 16(3):R57, 2014. PMID: 24890385

In revision:

90. Tang, B., Raviv, A., Esposito, D., Daniel, C., Nghiem, B-T., Garfield, S., Lim,L., Mannan, P., Robles, A.I., Smith, W.I., Zimmerberg, J., Ravin, R., and **Wakefield, L.M.** A Flexible Reporter for Direct Observation of Cancer Stem Cells.

91. Flanders, K.C., Heger, C.D, Conway, C., Tang, B.,Sato, M., Dengler, S.L., Goldsmith, P.K., Hewitt, S.M. and **Wakefield, L.M.** Brightfield Proximity Ligation Assay reveals both canonical and mixed TGF-beta/Smad signaling complexes in tissue sections.

BOOK CHAPTERS AND INVITED REVIEWS

1. Assoian, R.K., Roberts, A.B., **Wakefield, L.M.**, Anzano, M.A., and Sporn, M.B.: Transforming growth factors in non-neoplastic tissues and their role in controlling cell growth. In Feramisco, J., Ozanne, B., and Stiles, C. (Eds.): Cancer Cells . Cold Spring Harbor Laboratory Press,Vol. 3, pp. 59-64, 1985.

2. Sporn, M.B., Roberts, A.B., **Wakefield, L.M.**, and Assoian, R.K.: Transforming growth factor-ß: Biological function and chemical structure. Science 233: 532-534, 1986.

3. **Wakefield, L.M**.: An assay for type-ß transforming growth factor receptor. Methods in Enzymology 146: 167-173, 1987.

4. Sporn, M.B., Roberts, A.B., **Wakefield, L.M.**, and de Crombrugghe, B.: Some recent advances in the chemistry and biology of transforming growth factor-ß. J. Cell. Biol. 105: 1039-1045, 1987.

5. Roberts, A.B., Flanders, K.C., Kondaiah, P., Thompson, N.L., Van Obberghen-Schilling, E., **Wakefield, L.M.**, Rossi, P., de Crombrugghe, B., Heine, U., and Sporn, M.B.: Transforming growth factor-ß: biochemistry and roles in embryogenesis, tissue repair and remodeling, and carcinogenesis. Recent Prog. in Hormone Res. 44: 157-197, 1988.

6. **Wakefield, L.M**., Thompson, N.T., Flanders, K.C., O'Connor-McCourt, M.D., and Sporn, M.B.: Transforming growth factor-ß: multifunctional regulator of cell growth and phenotype. Annals N.Y. Acad. Sci. 551: 290-298, 1988.

7. **Wakefield, L.M.**, Thompson, N.T., O'Connor-McCourt, M.C., and Sporn, M.B.: Transforming growth factor-ß: and endogenous inhibitor of cells growth. Horizons in Endocrinology (M. Maggi, and C.A. Johnston, Eds.) Serono Symposia Publications 52: 21-29. Raven Press, New York, 1988.

8. **Wakefield, L.M.**, and Sporn, M.B.: Suppression of carcinogenesis: a role for TGF-ß and related molecules in the prevention of cancer. Tumor Suppressor Genes (G. Klein, ed.) Marcel Dekker Inc., New York: pp. 217-243, 1990.

9. **Wakefield, L.M**.: Growth Factors: an overview. Hormonal Communicating Events in the Testis (Isidori, A., Fabbri, A., Dufau, M.L., eds.) Serono Symposia Publications 70: 181-190, 1990.

10. **Wakefield, L**., Kim, S-J., Glick, A., Winokur, T., Colletta, A., and Sporn, M.: Regulation of transforming growth factor-ß subtypes by members of the steroid hormone superfamily. J. Cell Sci. Suppl. 13: 139-148, 1990.

11. **Wakefield, L.M.,** Colletta, A.A., McCune, B.K., and Sporn, M.B.: Roles for transforming growth factors-ß in the genesis, prevention, and treatment of breast cancer. Cancer Treat. Res. 61: 97-136 1992.

12. **Wakefield, L.M.**, Letterio, J.J., Geiser, A.G., Flanders, K.C., O'Shaughnessy, J., Roberts, A.B., and Sporn, M.B.: Transforming growth factors-ß in mammary tumorigenesis: promoters or antipromoters? Prog. Clin. and Biol. Res. 391:133-148, 1995

13. Cardiff, R.D., Anver, M.R., Gusterson, B.A., Hennighausen, L., Jensen, R.A., Merino, M.J., Rehm, S., Russo, J., Tavassoli, F.A., **Wakefield, L.M**., Ward, J.M., and Green, J.E.: The Mammary Pathology of Genetically Engineered Mice: The consensus report and recommendations from the Annapolis Meeting. Oncogene, 19:968-988, 2000.

14. **Wakefield, L.M.,** Yang Y., and Dukhanina, O.: Transforming growth factor-β and breast cancer: lessons learned from genetically altered mouse models. Breast Cancer Research, 2:100-106, 2000.

15. **Wakefield, L.M.,** Piek, E., and Bottinger, E.P.: TGF-β Signaling in Mammary Gland Development and Tumorigenesis. J. Mammary Gl. Biol. & Neoplasia, 6:67-82, 2001.

16. **Wakefield, L.M.**, and Roberts, A.B.: TGF-β signaling: Positive and Negative Effects on Tumorigenesis. Curr. Op. Genet. & Dev., 12:22-29, 2002.

17. Roberts, A.B. and **Wakefield, L.M.**: The two faces of TGF-β in carcinogenesis. Proc. Natl. Acad. Sci. USA, 100:8621-8623, 2003

18. Nam, J-S., Hirohashi, S. and **Wakefield, L.M.:** Dysadherin: A new player in cancer progression. Cancer Letters, 255:161-169, 2007.

19. **Wakefield, L.M.** and Hunter, K. Eds. Review issue on Metastasis. Breast Disease 26:1-2, 2006/7

20. **Wakefield,L.M** and Stuelten, C. Keeping order in the neighbourhood: new roles for TGF-β in maintaining epithelial homeostasis. Cancer Cell 12:293-295, 2007

21. Flanders, K.C. and **Wakefield, L.M.** Transforming growth factor-βs and mammary gland involution: functional roles and implications for cancer progression. J. Mammary Gland Biol. Neoplasia. 14:131-144, 2009

22. Laverty H.G., **Wakefield, L.M.,** Occleston, N.L., O'Kane, S., and Ferguson, M.W.J. TGF-β3 and Cancer. Cytokine and Growth Factor Reviews. 20:305-317, 2009

23. Luger, D. and **Wakefield, L.M.** Inflammation and beyond: complex roles for TGF-beta in the tumor microenvironment. In "The Inflammatory Milieu of Tumors: Cytokines and Chemokines that Affect Tumor Growth and Metastasis", pp121-152 Bentham Science Publishers, Ed: A. Ben-Baruch, 2012

24. **Wakefield, L.M.** and Hill, C.S. Beyond TGF-β: Roles of other TGF-β superfamily members in cancer. Nat. Rev. Cancer 13:328-341, 2013